Elion, the AI-powered research and intelligence platform for healthcare technology, announced the close of an oversubscribed $9.3 million seed round. The financing was led by existing Elion investor, NEA, with participation from new investors Cedars Sinai Health Ventures, TMV, Scrub Capital, and Alumni Ventures.

As generative AI and other advanced technologies transform healthcare, provider organisations are under growing pressure to make faster, smarter technology decisions. Yet most lack the structured intelligence, internal expertise, or dedicated resources needed to confidently evaluate an increasingly complex vendor landscape.

Elion is building the trusted platform healthcare leaders rely on for clear, credible insights into emerging technologies and the companies behind them. By combining a structured dataset of thousands of healthcare vendors with deep expertise in the workflows and decision-making dynamics of health systems, Elion delivers fast, high-quality guidance to help provider organisations evaluate solutions with confidence and clarity.

“We’re reimagining what a technology research and advisory business looks like in the age of generative AI,” said Bobby Guelich, Elion’s CEO and cofounder. “The starting point is our vendor marketplace, which has quickly become the go-to resource for health systems and provider organisations trying to make sense of a crowded and fast-changing landscape. The depth of our vendor and product intelligence, combined with our ability to deliver it in a structured, accessible format, is helping healthcare leaders make better, faster decisions.”